In January 2011, The Lancet published a statistic that should have made every policymaker in Delhi lose sleep: healthcare costs push 39 million Indians into poverty every year. In a country where insurance coverage is a thin gauze and government spending remains modest, out-of-pocket expenditure accounts for nearly four-fifths of total health spending.

The biggest culprit is not the surgeon’s fee, the ICU monitor, or the hospital bed. It is the medicine.

In rural India, nearly three-quarters of healthcare spending vanishes into the pharmacy. I did not need a journal to validate that number; I saw it unfold daily in Sevagram—quietly and repeatedly, like a slow leak that eventually empties a household. A daily-wage laborer would arrive breathless after a heart attack, or a farmer would be carried in after a snakebite. We would stabilize them and save them, but then, at the end of the encounter, we would hand them a prescription.

That piece of paper, so light in the doctor’s hand, was unbearably heavy in the patient’s life. To honor it, a man would sell his wife’s jewelry, mortgage his small plot of land, or borrow from a moneylender at interest rates that only desperation could justify. Healthcare had become the leading cause of rural debt, second only to the dowry. I realized then that we couldn’t just treat the disease; we had to treat the bill.

The biggest culprit is not the surgeon’s fee, the ICU monitor, or the hospital bed. It is the medicine.

***

The Theatre of Contradictions

The more I watched these families struggle, the more I asked: why are medicines so expensive? When I looked closely, the market appeared as a theatre of contradictions. The same molecule—atorvastatin, for instance—was sold by one company at ₹0.80 per tablet and by another at ₹8.00. This ten-fold difference was not a matter of science or quality; it was a matter of perception.

Market leaders charged a premium because they spent crores convincing doctors that their brand was “superior.” They created a monopoly not of molecules, but of minds. Then came the supply chain—the agents, stockists, and wholesalers—each adding a margin until the final markup reached 1000% or more. We could not fix the national market, but we could fix the market within our own walls.

***

The Drug and Therapeutics Committee

We formed a Drug and Therapeutics Committee (DTC)—not as a bureaucratic formality, but as a scalpel to cut away waste. Our goal was to bypass the inflated marketplace and build a direct pipeline from the manufacturer to the patient’s palm.

The first discipline was learning to say “no.” Instead of stocking every brand promoted by a medical representative, we created a list of essential medicines guided by WHO principles. We limited ourselves to two trusted brands per drug. Then came the negotiation. We invited tenders only from manufacturers with impeccable GMP compliance—Cipla, Ranbaxy, Dr. Reddy’s. Our pitch was blunt: “We buy directly. No middlemen. No marketing costs. Give us your factory price.”

***

When Prices Fell Like a Wall

When we stripped away the marketing and the margins, the prices didn’t just drop—they collapsed. The scale of the change made even our own pharmacists stare twice at the printouts.

These numbers changed more than just expenditure; they changed behavior. Families no longer abandoned treatment halfway through the course. Doctors no longer hesitated to prescribe what was clinically necessary out of fear for the patient’s wallet. We capped our own margin at 20%—just enough to cover electricity and salaries—and published a monthly Drug Bulletin by email to keep the system transparent and honest.

***

The Five-Rupee Dignity

In October 2010, we introduced the “Pink Slip” initiative for minor ailments. We identified 25 common medicines—painkillers, antacids, cough syrups—and pre-packed them. If a doctor prescribed up to three of these for three days, the patient paid a flat charge of ₹5.

For the cost of a cup of tea, a laborer could walk away with a course of treatment and the dignity of not having to borrow money for paracetamol. It was a small scheme, but it carried a big idea: equity must be designed, not merely wished for.

***

The ICU Lesson: Survival is Not Arithmetic

The true impact showed itself in the quiet of the ICU. A year earlier, treating severe sepsis was a financial catastrophe; a ten-day course of antibiotics could cost ₹30,000. Families would sit by the bedside counting breaths and the dwindling notes in their wallets, eventually asking, with shame, if we could stop treatment because the money had run out.

After our initiative, that same course cost ₹9,000. The difference between those two numbers is not arithmetic; it is survival. A breast cancer patient who once paid ₹10,000 for chemotherapy now paid ₹3,700. Sevagram taught me that “high cost” is often an artificial construct of a greedy market. If we can push prices down without compromising quality, economics becomes a tool for compassion. That, to me, is public health in its most practical, unvarnished form.

In January 2011, The Lancet published a statistic that should have made every policymaker in Delhi lose sleep: healthcare costs push 39 million Indians into poverty every year. In a country where insurance coverage is a thin gauze and government spending remains modest, out-of-pocket expenditure accounts for nearly four-fifths of total health spending.

The biggest culprit is not the surgeon’s fee, the ICU monitor, or the hospital bed. It is the medicine.

In rural India, nearly three-quarters of healthcare spending vanishes into the pharmacy. I did not need a journal to validate that number; I saw it unfold daily in Sevagram—quietly and repeatedly, like a slow leak that eventually empties a household. A daily-wage laborer would arrive breathless after a heart attack, or a farmer would be carried in after a snakebite. We would stabilize them and save them, but then, at the end of the encounter, we would hand them a prescription.

That piece of paper, so light in the doctor’s hand, was unbearably heavy in the patient’s life. To honor it, a man would sell his wife’s jewelry, mortgage his small plot of land, or borrow from a moneylender at interest rates that only desperation could justify. Healthcare had become the leading cause of rural debt, second only to the dowry. I realized then that we couldn’t just treat the disease; we had to treat the bill.